HOME >> BIOLOGY >> NEWS
Drug offers new options for leukemia patients

Dasatinib, an experimental drug under development by Bristol-Myers Squibb, reverses the signs and symptoms of patients whose chronic myeloid leukemia has failed to respond to Gleevec, which is considered the standard of treatment for the disorder.

In a study published in the June 15, 2006, issue of the New England Journal of Medicine (NEJM), Howard Hughes Medical Institute (HHMI) researchers at the University of California, Los Angeles, and colleagues at M.D. Anderson Cancer Center and Bristol-Myers Squibb in Princeton, NJ, report data from phase I human clinical trials of the compound, dasatinib (BMS-354825). Phase I clinical trials evaluate drug safety and toxicity at different dose levels in a small number of volunteers.

The studies published in NEJM indicate that dasatinib can be used to overcome Gleevec resistance in patients who have chronic myeloid leukemia (CML). Patients enrolled in the study had experienced a worsening of the disease or intolerance when treated with Gleevec.

Study leader, HHMI investigator Charles L. Sawyers, and colleagues at UCLA's Jonsson Comprehensive Cancer Center, report that dasatinib successfully circumvented Gleevec (imatinib) resistance in 68 of 84 patients treated with the drug during phase I clinical trials at UCLA and M.D. Anderson Cancer Center. Resistance to Gleevec develops when patients acquire mutations in an enzyme that is targeted by Gleevec.

"(The studies) provide immediate hope for patients in whom CML cells have developed resistance to imatinib," wrote HHMI investigator Brian J. Druker of Oregon Health and Science University in an accompanying editorial in NEJM. "They show that the pace of new drug development can be impressively rapid."

In early June 2006, the Food and Drug Administration's Oncologic Drugs Advisory Committee voted to recommend accelerated approval of dasatinib for the treatment of adults in all phases of CML with resistance or intolerance to prior therapy. The committee base
'"/>

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
14-Jun-2006


Page: 1 2 3

Related biology news :

1. UCF nanoparticle offers promise for treating glaucoma
2. Lucky 13 as new gene discovery offers further hope for childhood blindness
3. Largest synthetic gene ever built offers insights into anti-malarial drug resistance
4. Gene therapy offers new hope for treatment of peripheral neuropathy
5. Study of protein folds offers insight into metabolic evolution
6. Soy estrogens and breast cancer: Researcher offers overview
7. NIST building software offers green product advice
8. Study of planarians offers insight into germ cell development
9. Nanotechnology offers hope for treating spinal cord injuries, diabetes and Parkinsons disease
10. Research on grey mold offers possible breakthrough in tomato cultivation
11. RNA enzyme structure offers a glimpse into the origins of life

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... , ... July 02, 2020 ... ... Systems, B.V. (MBS) has announced a publication detailing the use of its ... transcription polymerase chain reaction (RT-PCR) in 16 minutes. The article, titled "Ultra-fast ...
(Date:6/28/2020)... BASEL, Switzerland (PRWEB) , ... ... ... leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that ... oncology company developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... gene-to-protein and monoclonal antibody development services, today announced that the company has ... services to the pharmaceutical, diagnostics, and research industries. The decision to pursue ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON ... of its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes ... globe, requiring fast track capacity to provide patients with urgently needed vaccines and ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... the leading global provider of advanced delivery technologies, development, and manufacturing solutions for ... they have entered into a strategic partnership whereby Catalent will provide support for ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... sciences industry, today announced the release of its signature product called Beacon ... Liaisons (MSLs) and other field medical professionals. , Beacon helps MSLs ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this new ... only technology of its kind on the market and we were pleased that the ... capacity of traditional cultured ingredients, creating a natural way to extend the shelf life ...
Breaking Biology Technology:
Cached News: